GEGANT

Radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing Gallium-68 for treating and diagnosing tumours; anti-cancer preparations, namely, Gallium-68 compounds, including 68-Ga chlorides; anti-cancer preparations, namely, Gallium-68 for use in the field of targeted radionuclide therapy of cancers, in particular prostate cancer and neuroendocrine tumours; cancer diagnostic preparations for medical purposes, namely, Gallium-68 compounds, including 68-Ga peptide chelates, in particular 68-Ga-Dotatoc and 68-Ga-Dotatate, 68-Ga salts, in particular 68-Ga chlorides; Gallium-68 for use as radiotracers in pet scans or combined PET/CT scans

Medical apparatus and instruments for use in positron emission tomography (PET) imaging, namely, Ge-68/Ga-68 radionuclide generators for pharmaceutical purposes as source of radionuclides being positron emitters in the field of Positron Emission Tomography - Computed Tomography (PET/CT)

Scientific and technological services and research on radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, services relating to radiopharmaceuticals for the therapy and diagnosis of diseases and services relating to radiopharmaceuticals coupled to somatostatin analogues for the diagnosis and treatment of tumours, namely, scientific and product research and development

Pharmaceutical advice in relation to radiopharmaceutical products, namely, 68-Ga products for use in medicine for third parties, namely, advice in relation to radiopharmaceuticals for the therapy and diagnosis of diseases, in particular tumour diseases, namely, pharmaceutical advice in relation to radiopharmaceuticals coupled to somatostatin analogues and advice in relation to the manufacture of personalised radiopharmaceutical products containing 68-Ga for use in medicine